Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof

The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-C...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Tsai, Chia-Ling, Chen, Yeh, Hung, Mien-Chie, Yang, Wen-Hao, Hou, Mei-Hui, Chou, Yi-Zhen, Wang, Yu-Quan, Yang, Chia-Shin, Hung, Chian-Fang, Huang, Bao-Yue, Hung, Yu-Lin
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.